Non-invasive Imaging of Therapy Response
-pdf
This talk will discuss the role of imaging in trials of anti-cancer
therapies. The need for improved biomarkers will be presented
and imaging will be introduced in this context. Although PET imaging
will be discussed, more emphasis will be placed on the use of
MRI (imaging) and MRS (spectroscopy) as endpoints to quantitatively
measure and predict therapy response. Specifically, the use of
Dynamic Contrast Enhanced (DCE) MRI, Diffusion MRI and proton
MRS will be discussed at the clinical, pre-clinical, in vitro
and theoretical levels.
|
